Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Stock Performance
BHC Stock opened at $5.84 on Tuesday. The firm has a market cap of $2.11 billion, a PE ratio of -5.12, a P/E/G ratio of 0.07 and a beta of 1.35. The firm's fifty day moving average is $7.98 and its 200 day moving average is $16.22. Bausch Health Companies has a one year low of $4.00 and a one year high of $29.59.
Bausch Health Companies (NYSE:BHC - Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.31). The company had revenue of $1.92 billion during the quarter, compared to analyst estimates of $2.06 billion. Bausch Health Companies had a negative net margin of 4.89% and a negative return on equity of 649.29%. Research analysts predict that Bausch Health Companies will post 3.85 earnings per share for the current fiscal year.
Analysts Set New Price Targets
BHC has been the subject of several recent research reports. Piper Sandler lowered their target price on shares of Bausch Health Companies from $27.00 to $7.00 in a report on Thursday, May 26th. StockNews.com downgraded shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Wednesday, May 11th. Bank of America cut their price objective on shares of Bausch Health Companies from $25.00 to $12.00 in a research report on Wednesday, May 11th. Royal Bank of Canada downgraded shares of Bausch Health Companies from an "outperform" rating to a "sector perform" rating and dropped their target price for the stock from $12.00 to $5.00 in a report on Friday, July 29th. Finally, BMO Capital Markets decreased their price target on shares of Bausch Health Companies from $26.00 to $15.00 in a research note on Wednesday, May 11th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Bausch Health Companies currently has a consensus rating of "Hold" and an average price target of $10.20.